Literature DB >> 10815908

Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network.

L M McShane1, R Aamodt, C Cordon-Cardo, R Cote, D Faraggi, Y Fradet, H B Grossman, A Peng, S E Taube, F M Waldman.   

Abstract

The National Cancer Institute Bladder Tumor Marker Network conducted a study to evaluate the reproducibility of immunohistochemistry for measuring p53 expression in bladder tumors. Fifty paraffin blocks (10 from each of the five network institutions) were chosen at random from among high-grade invasive primary bladder tumors. Two sections from each block were sent to each laboratory for staining and scoring, and then all sections were randomly redistributed among the laboratories for a second scoring. Intra- and interlaboratory reproducibility was assessed with regard to both staining and scoring. For overall assessments of p53 positivity, the results demonstrated that intralaboratory reproducibility was quite good. Concordance across the five participating laboratories was high for specimens exhibiting no or minimal nuclear immunostaining of tumor cells or high percentages of tumor cells with nuclear immunoreactivities. However, there was a reduced level of concordance on specimens with percentages of stained tumor cells in an intermediate range. The discordancies were due mainly to staining differences in one of the five laboratories and scoring differences in another laboratory. These results indicate that some caution must be used in comparing results across studies from different groups. Standardization of staining protocols and selection of a uniform threshold for binary interpretation of results may improve assay reproducibility between laboratories.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10815908

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

1.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  BMC Med       Date:  2012-05-29       Impact factor: 8.775

2.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

3.  False-positive lesions detected by fluorescence cystoscopy: any association with p53 and p16 expression?

Authors:  K Hendricksen; P M J Moonen; A G der Heijden; J A Witjes
Journal:  World J Urol       Date:  2006-09-22       Impact factor: 4.226

4.  A sample selection strategy to boost the statistical power of signature detection in cancer expression profile studies.

Authors:  Zhenyu Jia; Yipeng Wang; Yuanjie Hu; Christine McLaren; Yingyan Yu; Kai Ye; Xiao-Qin Xia; James A Koziol; Waldemar Lernhardt; Michael McClelland; Dan Mercola
Journal:  Anticancer Agents Med Chem       Date:  2013-02       Impact factor: 2.505

5.  Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks.

Authors:  M G W Bol; J P A Baak; B van Diermen; S Buhr-Wildhagen; E A M Janssen; K H Kjellevold; A J Kruse; O Mestad; P Øgreid
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

6.  Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin.

Authors:  Sultan S Alkhateeb; Mischel Neill; Sas Bar-Moshe; Bas Van Rhijn; David M Kakiashvili; Neil Fleshner; Michael Jewett; Michel Petein; Claude Schulman; Sally Hanna; Peter J Bostrom; Thierry Roumeguere; Shahrokh F Shariat; Sandrine Rorive; Alexandre R Zlotta
Journal:  Urol Ann       Date:  2011-09

7.  Use of latent class models to accommodate inter-laboratory variation in assessing genetic polymorphisms associated with disease risk.

Authors:  Stephen D Walter; Eduardo L Franco
Journal:  BMC Genet       Date:  2008-08-08       Impact factor: 2.797

8.  Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project.

Authors:  Gang Wang; Peter C Black; Peter J Goebell; Lingyun Ji; Carlos Cordon-Cardo; Bernd Schmitz-Dräger; Debra Hawes; Bogdan Czerniak; Sarah Minner; Guido Sauter; Frederic Waldman; Susan Groshen; Richard J Cote; Colin P Dinney
Journal:  Urol Oncol       Date:  2021-02-07       Impact factor: 2.954

9.  REporting recommendations for tumour MARKer prognostic studies (REMARK).

Authors:  L M McShane; D G Altman; W Sauerbrei; S E Taube; M Gion; G M Clark
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

10.  Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb.

Authors:  A W Hitchings; M Kumar; S Jordan; V Nargund; J Martin; D M Berney
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.